Molecular Biology of the Cell

Molecular Biology of the Cell PDF Author:
Publisher:
ISBN: 9780815332183
Category : Cells
Languages : en
Pages : 0

Get Book Here

Book Description

Molecular Biology of the Cell

Molecular Biology of the Cell PDF Author:
Publisher:
ISBN: 9780815332183
Category : Cells
Languages : en
Pages : 0

Get Book Here

Book Description


The Art and Politics of Science

The Art and Politics of Science PDF Author: Harold Varmus
Publisher: W. W. Norton & Company
ISBN: 0393073564
Category : Biography & Autobiography
Languages : en
Pages : 330

Get Book Here

Book Description
A Nobel Prize–winning cancer biologist, leader of major scientific institutions, and scientific adviser to President Obama reflects on his remarkable career. A PhD candidate in English literature at Harvard University, Harold Varmus discovered he was drawn instead to medicine and eventually found himself at the forefront of cancer research at the University of California, San Francisco. In this “timely memoir of a remarkable career” (American Scientist), Varmus considers a life’s work that thus far includes not only the groundbreaking research that won him a Nobel Prize but also six years as the director of the National Institutes of Health; his current position as the president of the Memorial Sloan-Kettering Cancer Center; and his important, continuing work as scientific adviser to President Obama. From this truly unique perspective, Varmus shares his experiences from the trenches of politicized battlegrounds ranging from budget fights to stem cell research, global health to science publishing.

How Tobacco Smoke Causes Disease

How Tobacco Smoke Causes Disease PDF Author: United States. Public Health Service. Office of the Surgeon General
Publisher:
ISBN:
Category : Government publications
Languages : en
Pages : 728

Get Book Here

Book Description
This report considers the biological and behavioral mechanisms that may underlie the pathogenicity of tobacco smoke. Many Surgeon General's reports have considered research findings on mechanisms in assessing the biological plausibility of associations observed in epidemiologic studies. Mechanisms of disease are important because they may provide plausibility, which is one of the guideline criteria for assessing evidence on causation. This report specifically reviews the evidence on the potential mechanisms by which smoking causes diseases and considers whether a mechanism is likely to be operative in the production of human disease by tobacco smoke. This evidence is relevant to understanding how smoking causes disease, to identifying those who may be particularly susceptible, and to assessing the potential risks of tobacco products.

RNA Tumor Viruses: Supplements and appendixes

RNA Tumor Viruses: Supplements and appendixes PDF Author:
Publisher:
ISBN:
Category : Oncogenic viruses
Languages : en
Pages : 1254

Get Book Here

Book Description


Medicinal Chemistry of Anticancer Drugs

Medicinal Chemistry of Anticancer Drugs PDF Author: Carmen Avendaño
Publisher: Elsevier
ISBN: 0444626670
Category : Science
Languages : en
Pages : 767

Get Book Here

Book Description
Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents. Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects. Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design. - Presents information in a clear and concise way using a large number of figures - Historical background provides insights on how the process of drug discovery in the anticancer field has evolved - Extensive references to primary literature

Comparative Oncology

Comparative Oncology PDF Author: Alecsandru Ioan Baba
Publisher:
ISBN: 9789732714577
Category : Electronic books
Languages : en
Pages : 787

Get Book Here

Book Description


The Status and Implications of Oncogene Research

The Status and Implications of Oncogene Research PDF Author: United States. Congress. House. Committee on Science and Technology. Subcommittee on Investigations and Oversight
Publisher:
ISBN:
Category : Cancer
Languages : en
Pages : 136

Get Book Here

Book Description


Her-2

Her-2 PDF Author: Robert Bazell
Publisher: Random House
ISBN: 0307764982
Category : Health & Fitness
Languages : en
Pages : 241

Get Book Here

Book Description
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.

Crafting Science

Crafting Science PDF Author: Joan H. Fujimura
Publisher: Harvard University Press
ISBN: 9780674175532
Category : History
Languages : en
Pages : 344

Get Book Here

Book Description
During the late 1970s and 1980s, "cancer" underwent a remarkable transformation. In one short decade, what had long been a set of heterogeneous diseases marked by uncontrolled cell growth became a disease of our genes. How this happened and what it means is the story Joan Fujimura tells in a rare inside look at the way science works and knowledge is created. A dramatic study of a new species of scientific revolution, this book combines a detailed ethnography of scientific thought, an in-depth account of science practiced and produced, a history of one branch of science as it entered the limelight, and a view of the impact of new genetic technologies on science and society. The scientific enterprise that Fujimura unfolds for us is proto-oncogene cancer research--the study of those segments of DNA now thought to make normal cells cancerous. Within this framework, she describes the processes of knowledge construction as a social enterprise, an endless series of negotiations in which theories, material technologies, and practices are co-constructed, incorporated, and refashioned. Along the way, Fujimura addresses long-standing questions in the history and philosophy of science, culture theory, and sociology of science: How do scientists create "good" problems, experiments, and solutions? What are the cultural, institutional, and material technologies that have to be in place for new truths and new practices to succeed? Portraying the development of knowledge as a multidimensional process conducted through multiple cultures, institutions, actors, objects, and practices, this book disrupts divisions among sociology, history, anthropology, and the philosophy of science, technology, and medicine.

The Heterogeneity of Cancer Metabolism

The Heterogeneity of Cancer Metabolism PDF Author: Anne Le
Publisher: Springer
ISBN: 331977736X
Category : Medical
Languages : en
Pages : 186

Get Book Here

Book Description
Genetic alterations in cancer, in addition to being the fundamental drivers of tumorigenesis, can give rise to a variety of metabolic adaptations that allow cancer cells to survive and proliferate in diverse tumor microenvironments. This metabolic flexibility is different from normal cellular metabolic processes and leads to heterogeneity in cancer metabolism within the same cancer type or even within the same tumor. In this book, we delve into the complexity and diversity of cancer metabolism, and highlight how understanding the heterogeneity of cancer metabolism is fundamental to the development of effective metabolism-based therapeutic strategies. Deciphering how cancer cells utilize various nutrient resources will enable clinicians and researchers to pair specific chemotherapeutic agents with patients who are most likely to respond with positive outcomes, allowing for more cost-effective and personalized cancer therapeutic strategies.